Quantitative HBsAg titer as predictor of response to therapy
- First Online:
- Cite this article as:
- Hadziyannis, E., Vassilopoulos, D. & Hadziyannis, S.J. Curr hepatitis rep (2009) 8: 169. doi:10.1007/s11901-009-0024-8
- 68 Downloads
The expanding availability of different potent antiviral agents for the treatment of chronic hepatitis B (CHB) has created optimism for achieving treatment goals, such as the loss of serum hepatitis B surface antigen (HBsAg), which represents the closest-to-cure outcome of chronic hepatitis B virus infection. Recent studies indicated the potential usefulness of HBsAg quantification during antiviral therapy (especially with interferon-α-based regimens) as a potential predictor of virologic response. This article critically reviews the most recent data regarding the value of measurements of HBsAg concentrations in predicting response in patients with hepatitis B e antigen (HBeAg)-positive and HBeAg-negative CHB treated with different antiviral agents.